Conor Killmurray

Despite researchers compiling data from an equal-access system and adjusting for age, diagnosis period, tumor stage, tumor histology/grade, and whether the patient had adjuvant treatment, the overall survival disparity between Black and White women with endometrial cancer persisted.

New NCCN guidelines are available for oncologists on treating and counseling patients with small cell lung cancer.

Results from a mantle cell lymphoma study provide critical real-world evidence for improved outcomes with evolving patterns of care in patients with mantle cell lymphoma, according to the study authors.

Tisotumab vedotin has become the first and only approved antibody-drug conjugate for the treatment of recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

In a presentation at the 2021 ESMO Congress, researchers discussed how nivolumab plus ipilimumab showed superior efficacy results after a 5-year follow-up in comparison to single-agent sunitinib.

According to new research, patients with a CDK12 mutation had a sensitivity to immune checkpoint inhibitors.

Disparities not only are widening among racial groups, but socioeconomic inequities should also be considered and addressed by the wider healthcare community, according to a lymphoma expert.

For patients with low-risk myelodysplastic syndrome, standardized treatment options are not readily available and dependent on the patient’s specific conditions.

With the development of anti-HER2 antibody-drug conjugates, clinicians are looking to expand the number of patients they can treat. Now, a new study shows that HER2-low-positive tumors can be identified as a new subgroup to help treat patients with HER2-positive breast cancer.

The Association of Community Cancer Centers released the results of their 2020 ACCC IO survey that showed how oncology professionals are looking to understand and take advantage of the growing immunotherapy treatment landscape.

A network meta-analysis looking at 4 studies that assessed atezolizumab/bevacizumab compared to lenvatinib showed there was not a statistically significant improvement for patients with unresectable hepatocellular carcinoma.

In an interview with Targeted Oncology, Rachel Wuerstein, MD, discussed the implications of the KAMILLA trial and the benefit of T-DM1. Wuerstein also discussed the data that show TDM1’s potential use for patients with HER2-positive metastatic breast cancer beyond the standard-of-care second-line setting.

Sequencing of over 5,000 cases of patients with metastatic castration resistant prostate cancer showed potential for identifying multiple biomarkers in MSH6-mutated cases.

The combination of paclitaxel and GSK2636771 showed encouraging antitumor activity and a manageable toxicity profile and in patients with PTEN-deficient advanced gastric cancer who progressed after first line chemotherapy.

The phase 3 LEAP-015 trial is actively looking at the efficacy and safety of the combination of pembrolizumab, lenvatinib, and chemotherapy in the first-line setting for patients with advanced gastroesophageal adenocarcinoma compared with chemotherapy alone.

A primary analysis of the phase 3 ZUMA-7 study shows the benefits of axicabtagene ciloleucel for patients with relapsed or refractory large B-cell lymphoma in the second and third-line settings.

New published data from a phase 2/3 trial shows the increased survival benefit of PD-1 inhibitor sintililmab and bevacizumab biosimilar IBI305 in the frontline setting for patients with metastatic HCC.

The FDA approved the use of avapritinib for patients with advanced systemic mastocytosis, aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.

Real world data looking at the use of the recently approved CAR T-cell therapies tisagenlecleucel and axicabtagene ciloleucel show that patients are receiving it prior to failing treatments and that 1 in 6 patients were experiencing relapse after treatment.

The first patient with an advanced solid tumor has been dosed in a phase 1 clinical trial of the multi-kinase inhibitor BTX-A51.

An updated analysis, presented at the 2021 ASCO Annual Meeting, showed encouraging signs for the combination of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.

In an updated analysis of the combination of lenvatinib and pembrolizumab for patients with advanced melanoma, efficacy results continue to show a durable response.

In a pharmacokinetic analysis of the first 15 patients in the phase 2 TBCRC049 study, researchers saw the first evidence for concentrations of tucatinib and ONT-993 in the cerebral spinal fluid of patients with HER2+ metastatic breast cancer with newly diagnosed leptomeningeal metastasis.

In a new survey from, a majority of oncologists are referring patients to CAR T-cell therapy but barriers to timely care still remain.

Data collected and analyzed from the Surveillance, Epidemiology, and End Results Medicare database showed that elderly patients with small-cell lung cancer had a substantial burden from myelosuppression events while on chemotherapy.

After receiving a complete response letter by the FDA, an approval application for ropeginterferon alfa-2b for treatment for patients with polycythemia vera. has been resubmitted to the FDA.

Potentially clinically actionable genomic alterations were identified in a majority of patients with advanced cancers with next-generation sequencing evaluated in a prospective study.

The LOTIS-2 phase 2 study of loncastuximab tesirine continued to show durable responses and tolerability in relapsed or refractory patients with DLBCL, according to the most recent published results.

Results from the phase 2 study of farnesyltransferase inhibitor tipifarnib showed significant responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma and demonstrated that variant alle frequency could be a potential biomarker in this patient population.

A new report on ibrutinib-resistant mantle cell lymphoma patient-derived xenograft mouse models shows the potential benefit of the EZH1/2 inhibitor OR-S1, as other similar inhibitors have shown benefit in patients with hematologic cancers.